Cancer genomics and precision oncology at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

26 organizations at ENA 2026 present work in cancer genomics, molecular profiling and precision oncology, led by cancer centres and hospitals. Between them they bring 68 presentations to the program. Most represented: MD Anderson Cancer Center, Vall d'Hebron Institute of Oncology (VHIO) and Gustave Roussy. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–7 of 26 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain
vhio.net Cancer centres & hospitals Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Session Wed Nov 18 1:35–2:20pm Keynote Lecture: The rise of biotech in APAC Session Wed Nov 18 2:20–3:50pm Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Immuno-oncology Talk Thu Nov 19 3:20–3:40pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Targeting YAP/TEAD as monotherapy and in rational combinations Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase Ib study of OMO-103 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma Targeted agents Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Talk Fri Nov 20 8:40–9am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Neoantigen TCR-T Cell therapy Talk Fri Nov 20 9:45–10am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development Multi-omics including Spatial Transcriptomics Early clinical Talk Fri Nov 20 12–12:10pm Part of Plenary Session 6: Proffered papers MYC Inhibition with OMO-103 Restores TNF-Superfamily Signaling and Uncovers Actionable Immunotherapy Vulnerabilities in KRAS-Mutant NSCLC Targeted agents · Immuno-oncology Session Fri Nov 20 3–4:50pm Plenary Session 7: Proffered papers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design Digital Remote Patient Monitoring in Early-Phase Oncology Clinical Trials: A Prospective Pilot Study of Feasibility and Implementation Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models A preclinical patient-derived xenograft platform to model resistance to cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in oestrogen receptor-positive breast cancer. Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Integrative molecular profiling of a breast cancer (BC) patient-derived xenograft (PDX) platform for biomarker discovery Preclinical models
Gustave Roussy Villejuif, France
gustaveroussy.fr Cancer centres & hospitals Comprehensive cancer centre combining patient care, research and teaching, with an early-phase drug development department.	Session Thu Nov 19 10–11:30am Plenary Session 3: Proffered Papers Talk Thu Nov 19 3–3:20pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise MTA-cooperative PRMT5 inhibitors in MTAP loss cancers Genomics Session Fri Nov 20 9:30–10:45am Workshop 7: Novel Methodologies & Endpoints in New Drug Development Early clinical Talk Fri Nov 20 10:15–10:30am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development AI Agents in Clinical Trials Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Cancer Genomics Genetic dissection of DNA damage tolerance pathways shaping tobacco-carcinogen-induced mutagenesis Genomics
The Institute of Cancer Research London, UK
icr.ac.uk Universities & institutes London cancer research institute and college of the University of London, with a drug discovery centre; partnered with The Royal Marsden.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Dissecting tumour microenvironment signatures associated with chemoresistance in triple negative breast cancer Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Functional Genomics Targeted protein degradation models for the exploration of spliceosome-associated RNA helicases as therapeutic targets Genomics Session Thu Nov 19 5–6:30pm Workshop 6: Tumour microenvironment Immuno-oncology Talk Thu Nov 19 6–6:20pm Part of Workshop 6: Tumour microenvironment Exploiting fibroblast activation protein (FAP) in cancer therapy Immuno-oncology
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global pharmaceutical company with oncology medicines in immunotherapy, cell therapy and protein degradation.	Talk Fri Nov 20 3:45–3:55pm Part of Plenary Session 7: Proffered papers BMS-986500: A novel molecular glue degrader of Cyclin E1 with first-in-class potential for treating CCNE1-amplified cancers and overcoming CDK4/6 inhibitor resistance in HR+ breast cancer Drug design · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Cancer Genomics Pathway Activity Inference Reveals Mechanistic Insights and Potential Therapeutic Vulnerabilities in MSS-CRC Molecular Subtypes Genomics
Children's Cancer Institute Sydney, Australia
ccia.org.au Universities & institutes Medical research institute focused on childhood cancer, including precision medicine and new treatments.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Functional Genomics Genome-wide Cas9 and subsequent focussed Cas13d screening identifies potential gene dependencies in diffuse midline glioma Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New agents for paediatric oncology Combined polyamine depletion and irinotecan drive durable tumour clearance in MYC-amplified Group 3 medulloblastoma Targeted agents
University of California, San Francisco San Francisco, CA
ucsf.edu Universities & institutes Health sciences university in San Francisco with a comprehensive cancer center and an academic medical center.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Molecular profiling A neural gene signature predicts recurrence of resected colorectal cancer liver metastases Genomics Talk Fri Nov 20 8:20–8:40am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Decoding CAR T cell function with CRISPR activation and interference Cell therapy